- Home
- EWTX vs CPRI Comparison
EWTX vs CPRI Comparison
Compare EWTX & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWTX | CPRI |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | EWTX | CPRI |
|---|---|---|
| Price | $28.57 | $20.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $34.71 | $27.08 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 03-02-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,326,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.75 |
| 52 Week Low | $10.60 | $11.86 |
| 52 Week High | $30.48 | $28.27 |
Technical Indicators
Market Signals| Indicator | EWTX | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 30.84 |
| Support Level | $27.07 | $22.32 |
| Resistance Level | $29.98 | $23.51 |
| Average True Range (ATR) | 1.54 | 1.16 |
| MACD | -0.06 | -0.48 |
| Stochastic Oscillator | 61.43 | 20.89 |
Price Performance
Historical ComparisonAbout EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.